SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton LJ III 1990 Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322: 802809.
  • 2
    Rodan GA, Fleisch HA 1996 Bisphosphonates: Mechanisms of action. J Clin Invest 97: 26922696.
  • 3
    Parfitt AM 2002 Targeted and nontargeted bone remodeling: Relationship to basic multicellular unit origination and progression. Bone 30: 57.
  • 4
    Parfitt AM 2002 The physiologic and pathogenetic significance of bone histomorphometric data. In: CoeFL, FavusMJ (eds.) Disorders of Bone and Mineral Metabolism, 2nd ed. Lippincott Williams and Wilkins, Philadelphia, PA, USA, pp. 469485.
  • 5
    Bouxsein ML 2001 Biomechanics of age-related fractures. In: MarcusR, FeldmanD, KelseyJ (eds.) Osteoporosis, 2nd ed. Academic Press, San Diego, CA, USA, pp. 509531.
  • 6
    Mosekilde L, Danielsen CC 1987 Biomechanical competence of vertebral trabecular bone in relation to ash density and age in normal individuals. Bone 8: 7985.
  • 7
    Beck TJ, Looker AC, Ruff CB, Sievanen H, Wahner HW 2000 Structural trends in the aging femoral neck and proximal shaft: Analysis of the third national health and nutrition examination survey dual-energy x-ray absorptiometry data. J Bone Miner Res 15: 22972304.
  • 8
    Bell GH, Dunbar O, Beck JS 1967 Variations in strength of vertebrae with age and their relation to osteoporosis. Calcif Tissue Res 1: 7586.
  • 9
    Parfitt AM, Mathews CHE, Villaneuva AR, Kleerekoper M, Frame B, Rao DS 1983 Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. J Clin Invest 72: 13961409.
  • 10
    Eriksen EF, Landgahl B, Vesterby A, Rungby J, Kassem M 1999 Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal women. J Bone Miner Res 14: 12171221.
  • 11
    Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 16411647.
  • 12
    Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. Am J Med 109: 267276.
  • 13
    Osteoporosis Methodology Group, Osteoporosis Research Advisory Group 2002 Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23: 495578.
  • 14
    Delmas PD, Hardy P, Garnero P, Dain M-P 2000 Monitoring individual response to hormone replacement therapy with bone markers. Bone 26: 553560.
  • 15
    Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC 1995 Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 99: 144152.
  • 16
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18: 10511056.
  • 17
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SAA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321333.
  • 18
    Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 14751480.
  • 19
    Vedi S, Purdie DW, Ballard P, Bord S, Cooper AC, Compston JE 1999 Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapy. Osteoporos Int 10: 5258.
  • 20
    Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL 1992 Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117: 19.
  • 21
    Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF 1996 A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11: 150159.
  • 22
    Weinstein RS, Chen J-R, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC 2002 Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109: 10411048.
  • 23
    Manolagas SC 2000 Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115137.
  • 24
    Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 2: 11321136.
  • 25
    Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T 1999 Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104: 13631374.
  • 26
    Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S 2000 Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106: 15531560.
  • 27
    Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG 2001 Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol 56A: M266M272.
  • 28
    Modelska K, Cummings S 2002 Tibolone for postmenopausal women: Systematic review of randomized trials. J Clin Endocrinol Metab 87: 1623.
  • 29
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel E-M, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster J-Y 2004 The effects of strontium ranelate on the risk of vertebral fractue in women with postmenopausal osteoporosis. N Engl J Med 350: 459468.
  • 30
    Parfitt AM 1980 Morphologic basis of bone mineral measurements: Transient and steady state effects of treatment in osteoporosis. Miner Electrolyte Metab 4: 273287.
  • 31
    Parfitt AM 1993 Pathophysiology of bone fragility. In: ChristiansenC, RiisB (eds.) Osteoporosis. Handelstrukkeriet Aalborg ApS, Aalborg, Denmark, pp. 164166.
  • 32
    Riggs BL 1993 Toward optimal therapy of established osteoporosis: Evidence that antiresorptive and formation-stimulating regimens reduce vertebral fractures by independent mechanisms Fourth International Symposium on Osteoporosis and Consensus Development Conference, Hong Kong, March 27-April 2, 1993, pp. 1315.
  • 33
    Riggs BL, Melton LJ III, O'Fallon WM 1996 Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 18(Suppl): 197S201S.
  • 34
    Riggs BL, Melton LJ 2001 Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17: 1114.
  • 35
    Sarkar S, Reginster J-Y, Crans GG, Diez-Perez A, Pinette KV, Delmas PD 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19: 394401.
  • 36
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15: 15261536.
  • 37
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17: 110.
  • 38
    Eastell R, Barton I, Hannon RA, Garnero P, Chines A, Pack S, Delmas PD 2002 Antifracture efficacy of risedronate: Prediction by change in bone resorption markers. IOF World Congress on Osteoporosis, Lisbon, Portugal, May 10–14, 2002.
  • 39
    Bauer DC, Black DM, Garnero P, Hochberg M, Ott SM, Schneider DL, Thompson D, Orloff J, Ewing S, Delmas PD 2002 Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate treated women: The fracture intervention trial. IOF World Congress on Osteoporosis, Lisbon, Portugal, May 10–14, 2002.
  • 40
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 14341441.
  • 41
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85: 21292134.
  • 42
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350: 550555.
  • 43
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 102: 16271633.
  • 44
    Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R 2003 Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88: 52125220.
  • 45
    Hodsman AB, Steer BM 1993 Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surfaces. Bone 14: 523527.
  • 46
    Dempster DW, Zhou H, Cosman F, Nieves J, Adachi JD, Frahar LJ, Watson PH, Lindsay B, Hodsman AB 2001 PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans. J Bone Miner Res 16: S1; S179.
  • 47
    Hock JM 1999 Stemming bone loss by suppressing apoptosis. J Clin Invest 104: 371373.
  • 48
    Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104: 439446.
  • 49
    Lindsay R, Zhou H, Cosman F, Bostrom M, Cruz JD, Nieves JW, Dempster DW 2003 Short term response to parathyroid hormone (1–34hPTH) in human iliac crest bone using a unique quadruple (double double) tetracycline labeling regimen and single biopsy. J Bone Miner Res 18: S1S54.
  • 50
    Parfitt AM 2002 Recent contributions of iliac bone histomorphometry to understanding the anabolic effect of parathyroid hormone. Available online at http://www.bonekey-ibms.org/cgi/content/full/ibmske; 2002017v1. Accessed June 15, 2004.
  • 51
    Balena R, Shih M-S, Parfitt AM 1992 Bone resorption and formation on the periosteal envelope of the ilium: A histomorphometric study in healthy women. J Bone Miner Res 7: 14751482.
  • 52
    Dobnig H, Turner RT 1995 Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136: 36323638.
  • 53
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16: 18461853.
  • 54
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18: 19321941.
  • 55
    Uusi-Rasi K, Beck TJ, Oreskovic TL, Sato M, Bogado CE, Zanchetta JR 2002 Teriparatide (rhPTH(1–34) improves the structural geometry of the hip. J Bone Miner Res 17: S1; S208.
  • 56
    Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE 2003 Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 14: 7781.
  • 57
    Rosen CJ, Wuster C 2003 Growth hormone rising: Did we quit too quickly. J Bone Miner Res 18: 406409.
  • 58
    Aaron JE, de Vernejoul MC, Kanis JA 1992 Bone hypertrophy and trabecular generation in Paget's disease and in fluoride-treated osteoporosis. Bone Miner 17: 399413.
  • 59
    Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R 2001 Treatment with human parathyroid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28: 150159.
  • 60
    Riggs BL, Melton LJ 1986 Medical progress series: Involutional osteoporosis. N Engl J Med 314: 16761686.
  • 61
    Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD 1994 Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 78: 955959.
  • 62
    Frost HM 1998 From Wolff's law to the mechanostat: A new “face” of physiology. J Orthop Sci 3: 282286.
  • 63
    Kousteni S, Chen J-R, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC 2002 Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298: 843846.